C$ unless otherwise stated – Form 6-K
C$ unless otherwise stated | TSX/NYSE/PSE: MFC | SEHK: 945 |
This earnings news release for
Manulife adopted IFRS 17 "Insurance Contracts" and IFRS 9 "Financial Instruments" effective for years beginning on
The comparative restated 2022 results in this news release may not be fully representative of our market risk profile, as the transition of our general fund portfolio for asset-liability matching purposes under IFRS 17 and IFRS 9 was not completed until early 2023. Consequently, year-over-year variations between our 2023 results compared to the restated 2022 results should be viewed in this context.
In addition, our restated 2022 results are also not directly comparable to 2023 results because IFRS 9 hedge accounting and expected credit loss ("ECL") principles are applied prospectively effective
Manulife reports 1Q23 net income attributed to shareholders of
Today, Manulife announced its first quarter of 2023 ("1Q23") results. This marks the first quarter of reporting under IFRS 17 and IFRS 9 and the transition impacts on our results are consistent with the guidance that we provided previously. Key highlights of 1Q23 include:
• |
Net income attributed to shareholders of |
• |
Core earnings1 of |
• |
Core EPS3 of |
• |
Core ROE3 of 14.8% and ROE of 13.6% in 1Q23 |
• |
APE sales4 of |
• |
NBV4 of |
• |
New business contractual service margin ("CSM")5 of |
• |
CSM balance net of NCI of |
1 |
Transitional net income attributed to shareholders, core earnings and post-tax CSM net of NCI ("post-tax CSM") are non-GAAP financial measures. For more information on non-GAAP and other financial measures, see "Non-GAAP and other financial measures" below and in our 1Q23 MD&A. |
2 |
Percentage growth / declines in core earnings, core EPS and new business CSM net of NCI stated on a constant exchange rate basis are non-GAAP ratios. |
3 |
Diluted core earnings per common share ("Core EPS"), transitional EPS and core retuon common shareholders' equity ("Core ROE") are non-GAAP ratios. |
4 |
For more information on new business value ("NBV") and annualized premium equivalent ("APE") sales, see "Non-GAAP and other financial measures" below. In this news release, percentage growth / declines in NBV and APE sales are stated on a constant exchange rate basis. |
5 |
New business contractual service margin is net of non-controlling interests ("NCI"). |
1 |
• |
Global Wealth and Asset Management ("Global WAM") net inflows1 of |
• |
LICAT ratio2 of 138% |
• |
Purchased for cancellation 0.8% of common shares outstanding, or approximately 15.6 million common shares, for |
• |
Adjusted book value per common share4 of |
• |
Embedded value1 of |
"We reported strong operating results in the first quarter of 2023 despite continued market volatility, delivering core earnings of
"As we report our first quarter of financial results under IFRS 17 and IFRS 9, I am pleased to confirm that the transition impacts are consistent with the guidance we provided previously," said
"Our financial strength, robust risk management and diversified business portfolio continue to drive the performance for our global franchise," added
BUSINESS HIGHLIGHTS:
In
1 |
For more information on net flows and embedded value, see "Non-GAAP and other financial measures" below. |
2 |
Life Insurance Capital Adequacy Test ("LICAT") ratio of The |
3 |
8.7 million shares were repurchased under the current Normal Course Issuer Bid ("NCIB") commenced on |
4 |
Adjusted book value per common share is a non-GAAP ratio. |
5 |
See "Caution regarding forward-looking statements" below. |
2 |
expanded access comes after a successful initial pilot when we became the first life insurance carrier to make the test available in
In addition, we continued to make progress on our digital journey in 1Q23. In
3 |
FINANCIAL HIGHLIGHTS:
Quarterly Results | ||||||||
($ millions, unless otherwise stated) | 1Q23 |
1Q22 Transitional |
||||||
Profitability: |
||||||||
Net income (loss) attributed to shareholders(1) |
$ | 1,406 | $ | 1,325 | ||||
Retuon common shareholders' equity ("ROE")(1) |
13.6% | 13.3% | ||||||
Diluted earnings (loss) per common share ($)(1) |
$ | 0.73 | $ | 0.66 | ||||
Quarterly Results | ||||||||
($ millions, unless otherwise stated) | 1Q23 | 1Q22 | ||||||
Profitability: |
||||||||
Net income (loss) attributed to shareholders |
$ | 1,406 | $ | (1,220) | ||||
Core earnings |
$ | 1,531 | $ | 1,393 | ||||
Diluted earnings per common share ("EPS") ($) |
$ | 0.73 | $ | (0.66) | ||||
Diluted core earnings per common share ("Core EPS") ($)(3) |
$ | 0.79 | $ | 0.69 | ||||
Retuon common shareholders' equity ("ROE") |
13.6% | (13.3)% | ||||||
Core ROE |
14.8% | 14.0% | ||||||
Expense efficiency ratio(3) |
47.1% | 46.4% | ||||||
Expenditure efficiency ratio(3) |
54.0% | 53.4% | ||||||
General expenses |
$ | 1,086 | $ | 931 | ||||
Core expenses(2) |
$ | 1,605 | $ | 1,416 | ||||
Core expenditures(2) |
$ | 2,112 | $ | 1,872 | ||||
Business performance: |
||||||||
Asia APE sales |
$ | 1,173 | $ | 1,087 | ||||
Canada APE sales |
$ | 293 | $ | 363 | ||||
|
$ | 134 | $ | 160 | ||||
Total APE sales |
$ | 1,600 | $ | 1,610 | ||||
|
$ | 372 | $ | 369 | ||||
|
$ | 92 | $ | 104 | ||||
|
$ | 45 | $ | 41 | ||||
Total new business value |
$ | 509 | $ | 514 | ||||
|
$ | 301 | $ | 317 | ||||
|
$ | 46 | $ | 61 | ||||
|
$ | 95 | $ | 112 | ||||
Total new business CSM |
$ | 442 | $ | 490 | ||||
Asia CSM net of NCI |
$ | 9,678 | $ | 9,045 | ||||
Canada CSM |
$ | 3,659 | $ | 3,903 | ||||
|
$ | 4,080 | $ | 3,892 | ||||
Corporate and Other CSM |
$ | 50 | $ | 27 | ||||
Total CSM net of NCI |
$ | 17,467 | $ | 16,867 | ||||
Post-tax CSM net of NCI(2) |
$ | 14,850 | $ | 14,320 | ||||
Global WAM net flows ($ billions) |
$ | 4.4 | $ | 6.8 | ||||
Global WAM gross flows ($ billions)(4) |
$ | 38.8 | $ | 38.4 | ||||
Global WAM assets under management and administration ($ billions)(2) |
$ | 814.5 | $ | 810.2 | ||||
Global WAM total invested assets ($ billions) |
$ | 5.6 | $ | 5.8 | ||||
Global WAM net segregated funds net assets ($ billions) |
$ | 235.6 | $ | 236.6 | ||||
Financial strength: |
||||||||
MLI's LICAT ratio |
138% | 140% | ||||||
Financial leverage ratio(3) |
26.0% | 24.9% | ||||||
Book value per common share ($) |
$ | 22.01 | $ | 20.11 | ||||
Adjusted book value per common share ($)(3) |
$ | 30.04 | $ | 27.53 |
(1) |
2022 results for transitional net income attributed to shareholders, transitional EPS and transitional ROE, a non-GAAP ratio, are adjusted to include IFRS 9 hedge accounting and expected credit loss principles ("IFRS 9 transitional impacts"). See 1Q23 MD&A for more information. For 2023, there are no IFRS 9 transitional adjustments as ECL and hedge accounting is effective |
(2) |
This item is a non-GAAP financial measure. See "Non-GAAP and other financial measures" below and in our 1Q23 MD&A for additional information. |
(3) |
This item is a non-GAAP ratio. |
(4) |
For more information on gross flows, see "Non-GAAP and other financial measures" below and in our 1Q23 MD&A. |
4 |
PROFITABILITY:
Reported net income attributed to shareholders of
Net income attributed to shareholders in 1Q23 was in line with 1Q22 transitional net income attributed to shareholders, reflecting higher core earnings largely offset by charges from market experience (compared with a small gain in the prior year on a transitional basis). The net charge from market experience in 1Q23 was primarily driven by lower-than-expected returns (including fair value changes) on alternative long duration assets ("ALDA") related to real estate and private equity, and a net realized loss from the sale of fixed income assets which are classified as fair value through other comprehensive income ("FVOCI"), partially offset by higher-than-expected returns on public equity, favourable foreign exchange impacts and a modest net gain from derivatives and hedge ineffectiveness. Net income attributed to shareholders in 1Q23 increased by
Delivered core earnings of
The increase in core earnings compared with 1Q22 was driven by the non-recurrence of excess mortality claims related to COVID-19 in 1Q22 in the
BUSINESS PERFORMANCE:
Annualized premium equivalent ("APE") sales of
In
New business value ("NBV") of
In
1 |
Variable fee approach ("VFA") |
2 |
Asia Other excludes |
3 |
Effective |
5 |
New business CSM of
In
CSM net of NCI was
The
Reported Global Wealth and Asset Management net inflows of
Net inflows in Retirement were
6 |
ADDITIONAL INFORMATION ON IFRS 17 AND IFRS 9
To accompany the release of our 1Q23 financial results we have published a video with presentation slides which provide a conceptual overview of our adoption of IFRS 17 and IFRS 9 as well as presentation slides on our 2022 comparative results. These materials are available under the "IFRS 17 Information" section on the Manulife website at: www.manulife.com/en/investors/results-and-reports.
QUARTERLY EARNINGS RESULTS CONFERENCE CALL
The conference call will also be webcast through Manulife's website at
The First Quarter 2023 Statistical Information Package is also available on the Manulife website at: www.manulife.com/en/investors/results-and-reports.
Any information contained in, or otherwise accessible through, websites mentioned in this news release does not form a part of this document unless it is expressly incorporated by reference.
Media Inquiries | Investor Relations | |
(416) 557-0945 | (416) 806-9921 | |
[email protected] | [email protected] |
7 |
EARNINGS:
The following table presents net income attributed to shareholders for 1Q23 and transitional net income attributed to shareholders for 1Q22 and 4Q22, consisting of core earnings and details of the items excluded from core earnings:
Quarterly Results | ||||||||||||
($ millions) | 1Q23 | 4Q22 | 1Q22 | |||||||||
Core earnings |
||||||||||||
|
$ | 489 | $ | 496 | $ | 479 | ||||||
|
353 | 296 | 334 | |||||||||
|
385 | 408 | 293 | |||||||||
Global Wealth and Asset Management |
287 | 274 | 344 | |||||||||
Corporate and Other |
17 | 69 | (57) | |||||||||
Total core earnings |
$ | 1,531 | $ | 1,543 | $ | 1,393 | ||||||
Items excluded from core earnings: |
||||||||||||
Market experience gains (losses) |
(65) | (655) | 3 | |||||||||
Change in actuarial methods and assumptions that flow directly through income |
- | - | - | |||||||||
Restructuring charge |
- | - | - | |||||||||
Reinsurance transactions, tax-related items and other |
(60) | 340 | (71) | |||||||||
Net income attributed to shareholders / Transitional(1) |
$ | 1,406 | $ | 1,228 | $ | 1,325 |
(1) |
This item is a non-GAAP financial measure. |
NON-GAAP AND OTHER FINANCIAL MEASURES:
The Company prepares its Consolidated Financial Statements in accordance with International Financial Reporting Standards ("IFRS") as issued by the
Non-GAAP financial measures include core earnings (loss); pre-tax core earnings; core earnings available to common shareholders; transitional net income (loss) attributed to shareholders; common shareholders' transitional net income; adjusted book value; post-tax contractual service margin; post-tax contractual service margin net of NCI ("post-tax CSM net of NCI"); total expenses; core expenses; total expenditures; core expenditures; and assets under management and administration ("AUMA").
Non-GAAP ratios include core retuon common shareholders' equity ("core ROE"); diluted core earnings per common share ("core EPS"); transitional retuon common shareholders' equity ("transitional ROE"); transitional diluted earnings per common share ("transitional diluted EPS"); expense efficiency ratio; expenditure efficiency ratio; financial leverage ratio; adjusted book value per common share and percentage growth/decline on a constant exchange rate basis in any of the above non-GAAP financial measures.
Other specified financial measures include assets under administration; embedded value; NBV; APE sales; gross flows; net flows; average assets under management and administration ("average AUMA") and percentage growth/decline in such other financial measures and new business CSM.
Non-GAAP financial measures and non-GAAP ratios are not standardized financial measures under GAAP and, therefore, might not be comparable to similar financial measures disclosed by other issuers. Therefore, they should not be considered in isolation or as a substitute for any other financial information prepared in accordance with GAAP. For more information on non-GAAP financial measures, including those referred to above, see the section "Non-GAAP and other financial measures" in our 2022 MD&A, which is incorporated by reference.
8 |
Reconciliation of core earnings to net income attributed to shareholders
1Q23 | ||||||||||||||||||||||||
($ millions, post-tax and based on actual foreign exchange rates in effect in the applicable reporting period, unless otherwise stated) |
Global WAM |
Corporate and Other |
Total | |||||||||||||||||||||
Income (loss) before income taxes |
$ | 613 | $ | 423 | $ | 219 | $ | 345 | $ | 119 | $ | 1,719 | ||||||||||||
Income tax (expense) recovery |
||||||||||||||||||||||||
Core earnings |
(68) | (85) | (86) | (45) | 14 | (270) | ||||||||||||||||||
Items excluded from core earnings |
(37) | (14) | 53 | (3) | (38) | (39) | ||||||||||||||||||
Income tax (expense) recovery |
(105) | (99) | (33) | (48) | (24) | (309) | ||||||||||||||||||
Net income (post-tax) |
508 | 324 | 186 | 297 | 95 | 1,410 | ||||||||||||||||||
Less: Net income (post-tax) attributed to |
||||||||||||||||||||||||
Non-controlling interests ("NCI") |
54 | - | - | - | - | 54 | ||||||||||||||||||
Participating policyholders |
(65) | 15 | - | - | - | (50) | ||||||||||||||||||
Net income (loss) attributed to shareholders (post-tax) |
519 | 309 | 186 | 297 | 95 | 1,406 | ||||||||||||||||||
Less: Items excluded from core earnings (post-tax) |
||||||||||||||||||||||||
Market experience gains (losses) |
30 | (44) | (166) | 9 | 106 | (65) | ||||||||||||||||||
Changes in actuarial methods and assumptions that flow directly through income |
- | - | - | - | - | - | ||||||||||||||||||
Restructuring charge |
- | - | - | - | - | - | ||||||||||||||||||
Reinsurance transactions, tax related items and other |
- | - | (33) | 1 | (28) | (60) | ||||||||||||||||||
Core earnings (post-tax) |
$ | 489 | $ | 353 | $ | 385 | $ | 287 | $ | 17 | $ | 1,531 | ||||||||||||
Income tax on core earnings (see above) |
68 | 85 | 86 | 45 | (14) | 270 | ||||||||||||||||||
Core earnings (pre-tax) |
$ | 557 | $ | 438 | $ | 471 | $ | 332 | $ | 3 | $ | 1,801 |
Core earnings, CER basis
1Q23 | ||||||||||||||||||||||||
(Canadian $ millions, post-tax and based on actual foreign exchange rates in effect in the applicable reporting period, unless otherwise stated) |
Global WAM |
Corporate and Other |
Total | |||||||||||||||||||||
Core earnings (post-tax) |
$ | 489 | $ | 353 | $ | 385 | $ | 287 | $ | 17 | $ | 1,531 | ||||||||||||
CER adjustment(1) |
- | - | - | - | - | - | ||||||||||||||||||
Core earnings, CER basis (post-tax) |
$ | 489 | $ | 353 | $ | 385 | $ | 287 | $ | 17 | $ | 1,531 | ||||||||||||
Income tax on core earnings, CER basis(2) |
68 | 85 | 86 | 45 | (14 | ) | 270 | |||||||||||||||||
Core earnings, CER basis (pre-tax) |
$ | 557 | $ | 438 | $ | 471 | $ | 332 | $ | 3 | $ | 1,801 |
(1) |
The impact of updating foreign exchange rates to that which was used in 1Q23. |
(2) |
Income tax on core earnings adjusted to reflect the foreign exchange rates for the Statement of Income in effect for 1Q23. |
9 |
Reconciliation of core earnings and transitional net income attributed to shareholders to net income attributed to shareholders
4Q22 | ||||||||||||||||||||||||
($ millions, post-tax and based on actual foreign exchange rates in effect in the applicable reporting period, unless otherwise stated) |
Global WAM |
Corporate and Other |
Total | |||||||||||||||||||||
Income (loss) before income taxes |
$ | 403 | $ | (37) | $ | (68) | $ | 461 | $ | (62) | $ | 697 | ||||||||||||
Income tax (expense) recovery |
||||||||||||||||||||||||
Core earnings |
(82) | (81) | (96) | (47) | 71 | (235) | ||||||||||||||||||
Items excluded from core earnings |
( 21) | 67 | 120 | (13) | 308 | 461 | ||||||||||||||||||
Income tax (expense) recovery |
(103) | (14) | 24 | (60) | 379 | 226 | ||||||||||||||||||
Net income (post-tax) |
300 | (51) | (44) | 401 | 317 | 923 | ||||||||||||||||||
Less: Net income (post-tax) attributed to |
||||||||||||||||||||||||
Non-controlling interests |
32 | - | - | - | 1 | 33 | ||||||||||||||||||
Participating policyholders |
(47) | 22 | - | - | - | (25) | ||||||||||||||||||
Net income (loss) attributed to shareholders (post-tax) |
315 | (73) | (44) | 401 | 316 | 915 | ||||||||||||||||||
IFRS 9 transitional impacts (post-tax) |
178 | 193 | (62) | - | 4 | 313 | ||||||||||||||||||
Transitional net income (loss) attributed to shareholders (post-tax) |
493 | 120 | (106) | 401 | 320 | 1,228 | ||||||||||||||||||
Less: Items excluded from core earnings (post-tax) |
||||||||||||||||||||||||
Market experience gains (losses) |
12 | (136) | (514) | 45 | (62) | (655) | ||||||||||||||||||
Changes in actuarial methods and assumptions that flow directly through income |
- | - | - | - | - | - | ||||||||||||||||||
Restructuring charge |
- | - | - | - | - | - | ||||||||||||||||||
Reinsurance transactions, tax related items and other |
(15) | (40) | - | 82 | 313 | 340 | ||||||||||||||||||
Core earnings (post-tax) |
$ | 496 | $ | 296 | $ | 408 | $ | 274 | $ | 69 | $ | 1,543 | ||||||||||||
Income tax on core earnings (see above) |
82 | 81 | 96 | 47 | (71) | 235 | ||||||||||||||||||
Core earnings (pre-tax) |
$ | 578 | $ | 377 | $ | 504 | $ | 321 | $ | (2) | $ | 1,778 |
Core earnings, CER basis
4Q22 | ||||||||||||||||||||||||
(Canadian $ millions, post-tax and based on actual foreign exchange rates in effect in the applicable reporting period, unless otherwise stated) |
Global WAM |
Corporate and Other |
Total | |||||||||||||||||||||
Core earnings (post-tax) |
$ | 496 | $ | 296 | $ | 408 | $ | 274 | $ | 69 | $ | 1,543 | ||||||||||||
CER adjustment(1) |
11 | - | (2) | (1) | - | 8 | ||||||||||||||||||
Core earnings, CER basis (post-tax) |
$ | 507 | $ | 296 | $ | 406 | $ | 273 | $ | 69 | $ | 1,551 | ||||||||||||
Income tax on core earnings, CER basis(2) |
80 | 82 | 95 | 48 | (71) | 234 | ||||||||||||||||||
Core earnings, CER basis (pre-tax) |
$ | 587 | $ | 378 | $ | 501 | $ | 321 | $ | (2) | $ | 1,785 |
(1) |
The impact of updating foreign exchange rates to that which was used in 1Q23. |
(2) |
Income tax on core earnings adjusted to reflect the foreign exchange rates for the Statement of Income in effect for 1Q23. |
10 |
Reconciliation of core earnings and transitional net income attributed to shareholders to net income attributed to shareholders
1Q22 | ||||||||||||||||||||||||
($ millions, post-tax and based on actual foreign exchange rates in effect in the applicable reporting period, unless otherwise stated) |
Global WAM |
Corporate and Other |
Total | |||||||||||||||||||||
Income (loss) before income taxes |
$ | 192 | $ | (1,038) | $ | (775) | $ | 336 | $ | (378) | $ | (1,663) | ||||||||||||
Income tax (expense) recovery |
||||||||||||||||||||||||
Core earnings |
(64) | (72) | (61) | (64) | 20 | (241) | ||||||||||||||||||
Items excluded from core earnings |
(9) | 455 | 237 | 11 | (13) | 681 | ||||||||||||||||||
Income tax (expense) recovery |
(73) | 383 | 176 | (53) | 7 | 440 | ||||||||||||||||||
Net income (post-tax) |
119 | (655) | (599) | 283 | (371) | (1,223) | ||||||||||||||||||
Less: Net income (post-tax) attributed to |
||||||||||||||||||||||||
Non-controlling interests |
2 | - | - | - | - | 2 | ||||||||||||||||||
Participating policyholders |
(22) | 17 | - | - | - | (5) | ||||||||||||||||||
Net income (loss) attributed to shareholders (post-tax) |
139 | (672) | (599) | 283 | (371) | (1,220) | ||||||||||||||||||
IFRS 9 transitional impacts (post-tax) |
66 | 998 | 1,484 | - | (3) | 2,545 | ||||||||||||||||||
Transitional net income (loss) attributed to shareholders (post-tax) |
205 | 326 | 885 | 283 | (374) | 1,325 | ||||||||||||||||||
Less: Items excluded from core earnings (post-tax) |
||||||||||||||||||||||||
Market experience gains (losses) |
(274) | (8) | 592 | (61) | (246) | 3 | ||||||||||||||||||
Changes in actuarial methods and assumptions that flow directly through income |
- | - | - | - | - | - | ||||||||||||||||||
Restructuring charge |
- | - | - | - | - | - | ||||||||||||||||||
Reinsurance transactions, tax related items and other |
- | - | - | - | (71) | (71) | ||||||||||||||||||
Core earnings (post-tax) |
$ | 479 | $ | 334 | $ | 293 | $ | 344 | $ | (57) | $ | 1,393 | ||||||||||||
Income tax on core earnings (see above) |
63 | 72 | 61 | 64 | (20) | 240 | ||||||||||||||||||
Core earnings (pre-tax) |
$ | 542 | $ | 406 | $ | 354 | $ | 408 | $ | (77) | $ | 1,633 |
Core earnings, CER basis
1Q22 | ||||||||||||||||||||||||
(Canadian $ millions, post-tax and based on actual foreign exchange rates in effect in the applicable reporting period, unless otherwise stated) |
Global WAM |
Corporate and Other |
Total | |||||||||||||||||||||
Core earnings (post-tax) |
$ | 479 | $ | 334 | $ | 293 | $ | 344 | $ | (57) | $ | 1,393 | ||||||||||||
CER adjustment(1) |
17 | - | 20 | 15 | 2 | 54 | ||||||||||||||||||
Core earnings, CER basis (post-tax) |
$ | 496 | $ | 334 | $ | 313 | $ | 359 | $ | (55) | $ | 1,447 | ||||||||||||
Income tax on core earnings, CER basis(2) |
65 | 72 | 65 | 66 | (20) | 248 | ||||||||||||||||||
Core earnings, CER basis (pre-tax) |
$ | 561 | $ | 406 | $ | 378 | $ | 425 | $ | (75) | $ | 1,695 |
(1) |
The impact of updating foreign exchange rates to that which was used in 1Q23. |
(2) |
Income tax on core earnings adjusted to reflect the foreign exchange rates for the Statement of Income in effect for 1Q23. |
11 |
Core earnings available to common shareholders
($ millions, and based on actual foreign exchange rates in effect in the applicable reporting period, unless otherwise stated)
Quarterly Results | Full Year Results |
|||||||||||||||||||||||
($ millions, and based on actual foreign exchange rates in effect in the applicable reporting period, unless otherwise stated) |
1Q23 | 4Q22 | 3Q22 | 2Q22 | 1Q22 | 2022 | ||||||||||||||||||
Core earnings |
$ | 1,531 | $ | 1,543 | $ | 1,339 | $ | 1,526 | $ | 1,393 | $ | 5,801 | ||||||||||||
Less: Preferred share dividends |
(52) | (97) | (51) | (60) | (52) | (260) | ||||||||||||||||||
Core earnings available to common shareholders |
1,479 | 1,446 | 1,288 | 1,466 | 1,341 | 5,541 | ||||||||||||||||||
CER adjustment(1) |
- | 8 | 38 | 64 | 54 | 164 | ||||||||||||||||||
Core earnings available to common shareholders, |
||||||||||||||||||||||||
CER basis |
$ | 1,479 | $ | 1,454 | $ | 1,326 | $ | 1,530 | $ | 1,395 | $ | 5,705 |
(1) |
The impact of updating foreign exchange rates to that which was used in 1Q23. |
Core ROE
($ millions, unless otherwise stated)
Quarterly Results | Full Year Results |
|||||||||||||||||||||||
($ millions, unless otherwise stated) | 1Q23 | 4Q22 | 3Q22 | 2Q22 | 1Q22 | 2022 | ||||||||||||||||||
Core earnings available to common shareholders |
$ | 1,479 | $ | 1,446 | $ | 1,288 | $ | 1,466 | $ | 1,341 | $ | 5,541 | ||||||||||||
Annualized core earnings available to common shareholders |
$ | 5,998 | $ | 5,737 | $ | 5,110 | $ | 5,880 | $ | 5,439 | $ | 5,541 | ||||||||||||
Average common shareholders' equity (see below) |
$ | 40,465 | $ | 40,667 | $ | 40,260 | $ | 39,095 | $ | 38,881 | $ | 39,726 | ||||||||||||
Core ROE (annualized) (%) |
14.8% | 14.1% | 12.7% | 15.1% | 14.0% | 14.0% | ||||||||||||||||||
Average common shareholders' equity |
||||||||||||||||||||||||
Total shareholders' and other equity |
$ | 47,375 | $ | 46,876 | $ | 47,778 | $ | 46,061 | $ | 44,459 | $ | 46,876 | ||||||||||||
Less: Preferred shares and other equity |
6,660 | 6,660 | 6,660 | 6,660 | 5,670 | 6,660 | ||||||||||||||||||
Common shareholders' equity |
$ | 40,715 | $ | 40,216 | $ | 41,118 | $ | 39,401 | $ | 38,789 | $ | 40,216 | ||||||||||||
Average common shareholders' equity |
$ | 40,465 | $ | 40,667 | $ | 40,260 | $ | 39,095 | $ | 38,881 | $ | 39,726 |
Transitional ROE
($ millions, unless otherwise stated)
Quarterly Results | Full Year Results |
|||||||||||||||||||
4Q22 | 3Q22 | 2Q22 | 1Q22 | 2022 | ||||||||||||||||
Common shareholders' transitional net income (loss) |
$ | 1,131 | $ | 726 | $ | 108 | $ | 1,273 | $ | 3,238 | ||||||||||
Annualized common shareholders' transitional net income (loss) |
$ | 4,487 | $ | 2,876 | $ | 437 | $ | 5,163 | $ | 3,238 | ||||||||||
Average common shareholders' equity |
$ | 40,667 | $ | 40,260 | $ | 39,095 | $ | 38,881 | $ | 39,726 | ||||||||||
Transitional ROE (annualized) (%) |
11.0% | 7.1% | 1.1% | 13.3% | 8.2% | |||||||||||||||
Quarterly Results | Full Year Results |
|||||||||||||||||||
4Q22 | 3Q22 | 2Q22 | 1Q22 | 2022 | ||||||||||||||||
Common shareholders' transitional net income (loss): |
||||||||||||||||||||
Total transitional net income (loss) attributed to shareholders |
$ | 1,228 | $ | 777 | $ | 168 | $ | 1,325 | $ | 3,498 | ||||||||||
Less: Preferred share dividends and other equity distributions |
(97) | (51) | (60) | (52) | (260) | |||||||||||||||
Common shareholders' transitional net income (loss) |
$ | 1,131 | $ | 726 | $ | 108 | $ | 1,273 | $ | 3,238 |
12 |
New Business CSM detail, CER Basis
($ millions pre-tax, and based on actual foreign exchange rates in effect in the applicable reporting period, unless otherwise stated).
1Q23 | 4Q22 | 3Q22 | 2Q22 | 1Q22 | 2022 | |||||||||||||||||||
New business CSM, net of NCI |
||||||||||||||||||||||||
|
$ | 119 | $ | 110 | $ | 127 | $ | 94 | $ | 106 | $ | 437 | ||||||||||||
|
36 | 28 | 37 | 38 | 37 | 140 | ||||||||||||||||||
Asia Other |
146 | 186 | 176 | 196 | 174 | 732 | ||||||||||||||||||
International High |
195 | |||||||||||||||||||||||
Mainland |
13 | |||||||||||||||||||||||
|
189 | |||||||||||||||||||||||
|
306 | |||||||||||||||||||||||
Other Emerging Markets |
29 | |||||||||||||||||||||||
|
301 | 324 | 340 | 328 | 317 | 1,309 | ||||||||||||||||||
|
46 | 47 | 44 | 47 | 61 | 199 | ||||||||||||||||||
|
95 | 71 | 86 | 118 | 112 | 387 | ||||||||||||||||||
Total new business CSM net of NCI |
442 | 442 | 470 | 493 | 490 | 1,895 | ||||||||||||||||||
Asia NCI |
19 | - | 2 | 1 | 17 | 20 | ||||||||||||||||||
Total impact of new insurance business in CSM |
$ | 461 | $ | 442 | $ | 472 | $ | 494 | $ | 507 | $ | 1,915 | ||||||||||||
New business CSM, net of NCI, CER adjustment(1) |
||||||||||||||||||||||||
|
$ | - | $ | (1) | $ | 4 | $ | 6 | $ | 8 | $ | 17 | ||||||||||||
|
- | 2 | 3 | 1 | (2) | 4 | ||||||||||||||||||
Asia Other |
- | 4 | 8 | 11 | 6 | 29 | ||||||||||||||||||
International High |
8 | |||||||||||||||||||||||
Mainland |
- | |||||||||||||||||||||||
|
14 | |||||||||||||||||||||||
|
7 | |||||||||||||||||||||||
Other Emerging Markets |
- | |||||||||||||||||||||||
|
- | 5 | 15 | 18 | 12 | 50 | ||||||||||||||||||
|
- | - | - | - | - | - | ||||||||||||||||||
|
- | - | 4 | 7 | 7 | 18 | ||||||||||||||||||
Total new business CSM net of NCI |
- | 5 | 19 | 25 | 19 | 68 | ||||||||||||||||||
Asia NCI |
- | - | - | - | - | - | ||||||||||||||||||
Total impact of new insurance business in CSM |
$ | - | $ | 5 | $ | 19 | $ | 25 | $ | 19 | $ | 68 | ||||||||||||
New Business CSM net of NCI, CER basis |
||||||||||||||||||||||||
|
$ | 119 | $ | 109 | $ | 131 | $ | 100 | $ | 114 | $ | 454 | ||||||||||||
|
36 | 30 | 40 | 39 | 35 | 144 | ||||||||||||||||||
Asia Other |
146 | 190 | 184 | 207 | 180 | 761 | ||||||||||||||||||
International High |
203 | |||||||||||||||||||||||
Mainland |
13 | |||||||||||||||||||||||
|
203 | |||||||||||||||||||||||
|
313 | |||||||||||||||||||||||
Other Emerging Markets |
29 | |||||||||||||||||||||||
|
301 | 329 | 355 | 346 | 329 | 1,359 | ||||||||||||||||||
|
46 | 47 | 44 | 47 | 61 | 199 | ||||||||||||||||||
|
95 | 71 | 90 | 125 | 119 | 405 | ||||||||||||||||||
Total new business CSM net of NCI, CER basis |
442 | 447 | 489 | 518 | 509 | 1,963 | ||||||||||||||||||
Asia NCI, CER basis |
19 | (1) | 2 | 1 | 17 | 19 | ||||||||||||||||||
Total impact of new insurance business in CSM, CER basis |
$ | 461 | $ | 446 | $ | 491 | $ | 519 | $ | 526 | $ | 1,982 |
(1) |
The impact of updating foreign exchange rates to that which was used in 1Q23. |
13 |
Post-tax CSM
($ millions and based on actual foreign exchange rates in effect in the applicable reporting period)
As at ($ millions) |
2023 |
2022 |
2022 |
2022 |
2022 |
|||||||||||||||
Post-tax CSM |
||||||||||||||||||||
CSM |
$ | 18,200 | $ | 17,977 | $ | 17,798 | $ | 17,452 | $ | 17,659 | ||||||||||
Marginal tax rate on CSM |
(2,724) | (2,726) | (2,632) | (2,595) | (2,667) | |||||||||||||||
Post-tax CSM |
$ | 15,476 | $ | 15,251 | $ | 15,166 | $ | 14,857 | $ | 14,992 | ||||||||||
CSM, net of NCI |
$ | 17,467 | $ | 17,283 | $ | 17,086 | $ | 16,711 | $ | 16,867 | ||||||||||
Marginal tax rate on CSM net of NCI |
(2,617) | (2,624) | (2,526) | (2,487) | (2,547) | |||||||||||||||
Post-tax CSM net NCI |
$ | 14,850 | $ | 14,659 | $ | 14,560 | $ | 14,224 | $ | 14,320 |
Adjusted book value
As at ($ millions) |
2023 |
2022 |
2022 |
2022 |
2022 |
|||||||||||||||
Common shareholders' equity |
$ | 40,715 | $ | 40,216 | $ | 41,118 | $ | 39,401 | $ | 38,789 | ||||||||||
Post tax CSM, net of NCI |
14,850 | 14,659 | 14,560 | 14,224 | 14,320 | |||||||||||||||
Adjusted book value |
$ | 55,565 | $ | 54,875 | $ | 55,678 | $ | 53,625 | $ | 53,109 |
Core expenses
($ millions, and based on actual foreign exchange rates in effect in the applicable reporting period, unless otherwise stated)
Quarterly Results | Full Year Results |
|||||||||||||||||||||||
1Q23 | 4Q22 | 3Q22 | 2Q22 | 1Q22 | 2022 | |||||||||||||||||||
Core expenses |
||||||||||||||||||||||||
General expenses - Statements of Income |
$ | 1,086 | $ | 1,002 | $ | 914 | $ | 884 | $ | 931 | $ | 3,731 | ||||||||||||
Directly attributable acquisition expense for contracts measured using the PAA method(1) |
33 | 15 | 17 | 15 | 11 | 58 | ||||||||||||||||||
Directly attributable maintenance expense(1) |
546 | 577 | 497 | 483 | 482 | 2,039 | ||||||||||||||||||
Total expenses |
$ | 1,665 | $ | 1,594 | $ | 1,428 | $ | 1,382 | $ | 1,424 | $ | 5,828 | ||||||||||||
Less: General expenses included in items excluded from core earnings |
||||||||||||||||||||||||
Restructuring charge |
- | - | - | - | - | - | ||||||||||||||||||
Integration and acquisition |
18 | - | - | 8 | 26 | |||||||||||||||||||
Legal provisions and Other expenses |
60 | - | 39 | 1 | - | 40 | ||||||||||||||||||
Total |
60 | 18 | 39 | 1 | 8 | 66 | ||||||||||||||||||
Core expenses |
$ | 1,605 | $ | 1,576 | $ | 1,389 | $ | 1,381 | $ | 1,416 | $ | 5,762 | ||||||||||||
CER adjustment(2) |
- | 7 | 34 | 44 | 45 | 130 | ||||||||||||||||||
Core expenses, CER basis |
$ | 1,605 | $ | 1,583 | $ | 1,423 | $ | 1,425 | $ | 1,461 | $ | 5,892 | ||||||||||||
Total expenses |
$ | 1,665 | $ | 1,594 | $ | 1,428 | $ | 1,382 | $ | 1,424 | $ | 5,828 | ||||||||||||
CER adjustment(2) |
- | 7 | 36 | 44 | 46 | 133 | ||||||||||||||||||
Total expenses, CER basis |
$ | 1,665 | $ | 1,601 | $ | 1,464 | $ | 1,426 | $ | 1,470 | $ | 5,961 |
(1) |
Expenses are components of insurance service expenses on the Statements of Income that flow directly to income. |
(2) |
The impact of updating foreign exchange rates to that which was used in 1Q23. |
14 |
Core expenditures
($ millions, and based on actual foreign exchange rates in effect in the applicable reporting period, unless otherwise stated)
Quarterly Results | Full Year Results |
|||||||||||||||||||||||
1Q23 | 4Q22 | 3Q22 | 2Q22 | 1Q22 | 2022 | |||||||||||||||||||
Core expenditures |
||||||||||||||||||||||||
Total expenses |
$ | 1,665 | $ | 1,594 | $ | 1,428 | $ | 1,382 | $ | 1,424 | $ | 5,828 | ||||||||||||
Directly attributable acquisition expenses capitalized through the CSM(1) |
507 | 532 | 467 | 454 | 456 | 1,909 | ||||||||||||||||||
Total expenditures |
2,172 | 2,126 | 1,895 | 1,836 | 1,880 | 7,737 | ||||||||||||||||||
Less: General expenses included in items excluded from core earnings (see core expenses reconciliation above) |
60 | 18 | 39 | 1 | 8 | 66 | ||||||||||||||||||
Core expenditures |
$ | 2,112 | $ | 2,108 | $ | 1,856 | $ | 1,835 | $ | 1,872 | $ | 7,671 | ||||||||||||
CER adjustment(2) |
- | 14 | 54 | 62 | 55 | 185 | ||||||||||||||||||
Core expenditures, CER basis |
$ | 2,112 | $ | 2,122 | $ | 1,910 | $ | 1,897 | $ | 1,927 | $ | 7,856 | ||||||||||||
Total expenditures |
$ | 2,172 | $ | 2,126 | $ | 1,895 | $ | 1,836 | $ | 1,880 | $ | 7,737 | ||||||||||||
CER adjustment(2) |
- | 15 | 56 | 61 | 56 | 188 | ||||||||||||||||||
Total expenditures, CER basis |
$ | 2,172 | $ | 2,141 | $ | 1,951 | $ | 1,897 | $ | 1,936 | $ | 7,925 |
1) |
Expenses are components of insurance service expenses on the Statements of Income and are then capitalized to CSM. |
2) |
The impact of updating foreign exchange rates to that which was used in 1Q23. |
Global WAM AUMA reconciliation
As at | ||||||||||||||||||||
($ millions, and based on actual foreign exchange rates in effect in the applicable reporting period, unless otherwise stated) |
2023 |
2022 |
2022 |
2022 |
2022 |
|||||||||||||||
Total invested assets |
$ | 412,476 | $ | 400,142 | $ | 396,583 | $ | 391,098 | $ | 404,023 | ||||||||||
Less: Non Global WAM total invested assets |
406,911 | 394,390 | 390,997 | 385,400 | 398,222 | |||||||||||||||
Total invested assets - Global WAM |
5,565 | 5,752 | 5,586 | 5,698 | 5,801 | |||||||||||||||
Total segregated funds net assets |
$ | 364,044 | $ | 348,562 | $ | 335,245 | $ | 334,903 | $ | 371,926 | ||||||||||
Less: Non Global WAM total segregated funds net assets |
128,466 | 124,371 | 120,776 | 121,624 | 135,314 | |||||||||||||||
Total invested assets - Global WAM |
235,578 | 224,191 | 214,469 | 213,279 | 236,612 | |||||||||||||||
Global WAM total invested assets and net segregated funds assets |
$ | 241,143 | $ | 229,943 | $ | 220,055 | $ | 218,977 | $ | 242,413 | ||||||||||
Global WAM AUMA |
||||||||||||||||||||
Total invested assets |
$ | 5,565 | $ | 5,752 | $ | 5,586 | $ | 5,698 | $ | 5,801 | ||||||||||
Segregated funds net assets |
||||||||||||||||||||
Segregated funds net assets - Institutional |
3,718 | 3,719 | 4,118 | 4,098 | 4,336 | |||||||||||||||
Segregated funds net assets - Other |
231,860 | 220,472 | 210,351 | 209,181 | 232,276 | |||||||||||||||
Total |
235,578 | 224,191 | 214,469 | 213,279 | 236,612 | |||||||||||||||
Mutual funds |
267,767 | 258,273 | 249,591 | 250,517 | 274,733 | |||||||||||||||
Institutional asset management(1) |
113,781 | 109,739 | 100,474 | 96,997 | 98,177 | |||||||||||||||
Other funds |
14,302 | 13,617 | 12,910 | 15,075 | 16,023 | |||||||||||||||
Total Global WAM AUM |
636,993 | 611,572 | 583,030 | 581,566 | 631,346 | |||||||||||||||
Assets under administration |
177,510 | 170,768 | 168,316 | 165,197 | 178,843 | |||||||||||||||
Total Global WAM AUMA |
$ | 814,503 | $ | 782,340 | $ | 751,346 | $ | 746,763 | $ | 810,189 | ||||||||||
Total Global WAM AUMA |
$ | 814,503 | $ | 782,340 | $ | 751,346 | $ | 746,763 | $ | 810,189 | ||||||||||
CER adjustment(2) |
- | (396) | (5,941) | 26,727 | 45,590 | |||||||||||||||
Total Global WAM AUMA, CER basis |
$ | 814,503 | $ | 781,944 | $ | 745,405 | $ | 773,490 | $ | 855,779 |
(1) |
Institutional asset management excludes Institutional segregated funds net assets. |
(2) |
The impact of updating foreign exchange rates to that which was used in 1Q23. |
15 |
CAUTION REGARDING FORWARD-LOOKING STATEMENTS:
From time to time, Manulife makes written and/or oral forward-looking statements, including in this document. In addition, our representatives may make forward-looking statements orally to analysts, investors, the media and others. All such statements are made pursuant to the "safe harbour" provisions of Canadian provincial securities laws and the
The forward-looking statements in this document include, but are not limited to, statements with respect to possible share buybacks under our NCIB, our ability to achieve our medium-term financial and operating targets and also relate to, among other things, our objectives, goals, strategies, intentions, plans, beliefs, expectations and estimates, and can generally be identified by the use of words such as "may", "will", "could", "should", "would", "likely", "suspect", "outlook", "expect", "intend", "estimate", "anticipate", "believe", "plan", "forecast", "objective", "seek", "aim", "continue", "goal", "restore", "embark" and "endeavour" (or the negative thereof) and words and expressions of similar import, and include statements concerning possible or assumed future results. Although we believe that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements and they should not be interpreted as confirming market or analysts' expectations in any way.
Certain material factors or assumptions are applied in making forward-looking statements and actual results may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from expectations include but are not limited to: general business and economic conditions (including but not limited to the performance, volatility and correlation of equity markets, interest rates, credit and swap spreads, inflation rates, currency rates, investment losses and defaults, market liquidity and creditworthiness of guarantors, reinsurers and counterparties); the ongoing prevalence of COVID-19, including any variants, as well as actions that have been, or may be taken by governmental authorities in response to COVID-19, including the impacts of any variants; changes in laws and regulations; changes in accounting standards applicable in any of the territories in which we operate; changes in regulatory capital requirements; our ability to obtain premium rate increases on in-force policies; our ability to execute strategic plans and changes to strategic plans; downgrades in our financial strength or credit ratings; our ability to maintain our reputation; impairments of goodwill or intangible assets or the establishment of provisions against future tax assets; the accuracy of estimates relating to morbidity, mortality and policyholder behaviour; the accuracy of other estimates used in applying accounting policies, actuarial methods and embedded value methods; our ability to implement effective hedging strategies and unforeseen consequences arising from such strategies; our ability to source appropriate assets to back our long-dated liabilities; level of competition and consolidation; our ability to market and distribute products through current and future distribution channels; unforeseen liabilities or asset impairments arising from acquisitions and dispositions of businesses; the realization of losses arising from the sale of investments classified fair value through other comprehensive income; our liquidity, including the availability of financing to satisfy existing financial liabilities on expected maturity dates when required; obligations to pledge additional collateral; the availability of letters of credit to provide capital management flexibility; accuracy of information received from counterparties and the ability of counterparties to meet their obligations; the availability, affordability and adequacy of reinsurance; legal and regulatory proceedings, including tax audits, tax litigation or similar proceedings; our ability to adapt products and services to the changing market; our ability to attract and retain key executives, employees and agents; the appropriate use and interpretation of complex models or deficiencies in models used; political, legal, operational and other risks associated with our non-North American operations; geopolitical uncertainty, including international conflicts; acquisitions and our ability to complete acquisitions including the availability of equity and debt financing for this purpose; the disruption of or changes to key elements of the Company's or public infrastructure systems; environmental concerns, including climate change; our ability to protect our intellectual property and exposure to claims of infringement; and our inability to withdraw cash from subsidiaries.
Additional information about material risk factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found under "Risk Management and Risk Factors" and "Critical Actuarial and Accounting Policies" in the Management's Discussion and Analysis in our most recent annual report, under "Risk Management and Risk
16 |
Factors Update" and "Critical Actuarial and Accounting Policies" in the Management's Discussion and Analysis in our most recent interim report, in the "Risk Management" note to the Consolidated Financial Statements in our most recent annual and interim reports, as well as elsewhere in our filings with Canadian and
The forward-looking statements in this document are, unless otherwise indicated, stated as of the date hereof and are presented for the purpose of assisting investors and others in understanding our financial position and results of operations, our future operations, as well as our objectives and strategic priorities, and may not be appropriate for other purposes. We do not undertake to update any forward-looking statements, except as required by law.
17 |
Attachments
Disclaimer
Slides – Conceptual overview of Manulife's adoption of IFRS 17 and IFRS 9
New Findings in Health and Medicine Described from University of California (Association Between a Capitated, Low-cost, County-Based Public Health Insurance Option and Affordable Care Act Premium Growth in California): Health and Medicine
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News